Clinical Study of Aumolertinib Versus Osimertinib in the Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Shengxi YANG; Jiade ZHU; Qiurui LI; Wenlian TU

Article Contents

Article Navigation > Journal of Kunming Medical University > 2025 > Accepted Manuscript

Shengxi YANG, Jiade ZHU, Qiurui LI, Wenlian TU. Clinical Study of Aumolertinib Versus Osimertinib in the Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer[J]. Journal of Kunming Medical University.

Citation:

Shengxi YANG, Jiade ZHU, Qiurui LI, Wenlian TU. Clinical Study of Aumolertinib Versus Osimertinib in the Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer[J]. Journal of Kunming Medical University.

Citation:

PDF( 814 KB)

Clinical Study of Aumolertinib Versus Osimertinib in the Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Shengxi YANG^{1, 2},
Jiade ZHU²,
Qiurui LI³,
Wenlian TU^{1
,
,}

1.
Dept. of Pharmacy，The 1st People’s Hospital of Yunnan/Kunhua Hospital Affiliated to Kunming University of Science and Technology，Kunming Yunnan 650032
2.
College of Pharmacy，Dali University，Dali Yunnan 671000
3.
Dept. of Pharmacy，The People’s Hospital of Chuxiong Yi Autonomo，Chuxiong Yunnan 675000，China

Received Date: 2024-07-19
Available Online: 2024-11-23

Abstract

Abstract

Objective To compare the efficacy and safety of osimertinib and aumolertinib in the treatment of advanced non-small cell lung carcinoma （NSCLC） with epidermal growth factor receptor （EGFR） mutation. Methods A total of 139 patients with EGFR-mutated advanced NSCLC treated in the First People's Hospital of Yunnan Province from January, 2019 to December, 2022 were retrospectively collected. After screening by that row of criteria, 104 patients were included in this study. According to the treatment drugs, they were divided into osimertinib group and aumolertinib group, with 52 cases in each group. The osimertinib group received osimertinib mesylate tablets 80 mg once daily, and the aumolertinib group received aumolertinib mesylate tablets 110 mg once daily. The disease control rate （DCR）, objective remission rate （ORR） and progression-free survival （PFS） of the two groups were observed. PFS and overall survival （OS） were evaluated. The Cox regression model was used to analyze the key factors affecting patient survival. Results The ORR of aumolertinib group was significantly higher than that of osimertinib group. The median progression-free survival （mPFS） of aumolertinib group was significantly longer than that of osimertinib group （P = 0.045）. Cox regression model showed that clinical stage Ⅲ（HR = 2.25, 95%Cl 1.28～3.95, P = 0.005）, no brain metastasis （HR = 0.59, 95%Cl 0.35～0.98, P = 0.040）, third generation TKI type aumolertinib （HR = 1.82, 95%CI 1.15～2.87, P = 0.011）. Conclusion Aumolertinib and osimertinib have similar clinical efficacy in the treatment of advanced NSCLC patients with EGFR mutation. However, in terms of long-term efficacy, aumolertinib has significantly better median PFS and overall OS, and higher safety than osimertinib.
- Osimertinib,
- Aumolertinib,
- Clinical efficacy,
- Adverse drug reactions,
- Non-small cell lung cancer

FullText(HTML)

References(23)

References

[1]	赵媛媛,周建英,范云,等. BRAF V600突变型非小细胞肺癌的治疗进展[J]. 中国癌症杂志,2021,31(12):1145-1152.
[2]	中华医学会肿瘤学分会,中华医学会杂志社. 中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J]. 中华医学杂志,2021,101(23):1725-1757.
[3]	Giaccone G,He Y. Current knowledge of small cell lung cancer transformation from non-small cell lung cancer [C] //Seminars in Cancer Biology. Academic Press,2023,94: 1-10.
[4]	Miller K D,Nogueira L,Devasia T,et al. Cancer treatment and survivorship statistics,2022[J]. CA: A Cancer Journal for Clinicians,2022,72(5):409-436. doi: 10.3322/caac.21731
[5]	吴方雨,陈卫东,夏盼盼,等. 埃克替尼对比吉非替尼治疗EGFR突变型晚期NSCLC的临床观察[J]. 中国药房,2023,34(10):1228-1232. doi: 10.6039/j.issn.1001-0408.2023.10.14
[6]	左强,江国强,方芳,等. 伏美替尼治疗EGFR突变阳性非小细胞肺癌EGFR-TKI耐药患者的临床观察[J]. 中国现代医学杂志,2022,32(14):30-34.
[7]	王皓,曾晨欣,李俐,等. 奥希替尼和吉非替尼/厄洛替尼一线治疗EGFR突变阳性非小细胞肺癌的成本-效果分析[J]. 医药导报,2020,39(12):1689-1696.
[8]	张聪,史琛,解吉奕,等. 阿美替尼治疗非小细胞肺癌的研究进展[J]. 中国医院药学杂志,2022,42(15):1613-1618.
[9]	Fu K,Xie F,Wang F,et al. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance[J]. Journal of Hematology & Oncology,2022,15(1):173.
[10]	Cheng Z,Cui H,Wang Y,et al. The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer[J]. Oncology Reports,2024,51(1):1-13.
[11]	Du X,Yang B,An Q,et al. Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors[J]. The Innovation,2021,2(2):1-17.
[12]	Zhang X,Zhang M,Du X,et al. Clinical efficacy and safety analysis of aumolertinib in real-world treatment of EGFR-mutated advanced non-small-cell lung cancer[J]. Frontiers in Pharmacology,2024,15(9):1331138.
[13]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南2023版 [M]. 北京: 人民卫生出版社,2023: 16-17.
[14]	孟新源,张莉,薛淑萍. EGFR突变晚期NSCLC患者第1、2代EGFR-TKI治疗耐药后序贯奥希替尼或阿美替尼治疗的效果观察[J]. 中国医院用药评价与分析,2023,23(9):1079-1081+1085.
[15]	杨光霞,程云涛,刘琳琳,等. 阿美替尼片联合贝伐珠单抗注射液治疗表皮生长因子受体突变的晚期非小细胞肺癌患者的临床研究[J]. 中国临床药理学杂志,2023,39(11):1528-1532.
[16]	Blonde L,Khunti K,Harris S B,et al. Interpretation and impact of real-world clinical data for the practicing clinician[J]. Advances in therapy,2018,35(11):1763-1774. doi: 10.1007/s12325-018-0805-y
[17]	Wang J,Wu L. An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer[J]. Expert Opinion on Pharmacotherapy,2022,23(6):647-652. doi: 10.1080/14656566.2022.2050213
[18]	Lu S,Wang Q,Zhang G,et al. Efficacy of aumolertinib (HS-10296) in patients with advanced EGFR T790M+ NSCLC: updated post-national medical products administration approval results from the APOLLO registrational trial[J]. Journal of Thoracic Oncology,2022,17(3):411-422. doi: 10.1016/j.jtho.2021.10.024
[19]	Zhou Q,Zhang H L,Jiang L Y,et al. Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study[J]. Journal of Cancer Research and Clinical Oncology,2023,149(12):10771-10780.
[20]	Ramalingam S S,Vansteenkiste J,Planchard D,et al. Overall survival with osimertinib in untreated,EGFR-mutated advanced NSCLC[J]. New England Journal of Medicine,2020,382(1):41-50. doi: 10.1056/NEJMoa1913662
[21]	Soria J C,Ohe Y,Vansteenkiste J,et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer[J]. New England Journal of Medicine,2018,378(2):113-125. doi: 10.1056/NEJMoa1713137
[22]	Shirley M,Keam S J. Aumolertinib: a review in non-small cell lung cancer[J]. Drugs,2022,82(5):577-584. doi: 10.1007/s40265-022-01695-2
[23]	Li H,Zhao W,Chang C,et al. Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study[J]. Frontiers in Pharmacology,2024,15(6):1444707.

Relative Articles(20)

Relative Articles

[1]	Yingyuan ZHANG, Chunyan MOU, Huan MU, Danqing XU, Lixian CHANG, Yuanzhen WANG, Chunyun LIU, Li LIU. Comparison of Efficacy of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate on Chronic Hepatitis B. Journal of Kunming Medical University,
[2]	Chao HONG, Xudong XIANG, Yingfu LI, Yang CAO, Xueya CHEN, Shuai LI, Anhao XING, Mu LIN, Qianli MA. Association of Polymorphisms in the 3' UTR of Genes in the ERK1/2 Signaling Pathway with Non-small Cell Lung Cancer. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20240302
[3]	Caini ZHANG, Ya LI. A Meta-analysis of the Efficacy and Safety of Camrelizumab Combined with Chemotherapy in the Treatment of Non-small Cell Lung Cancer. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20240610
[4]	Hongbo ZHANG, Zhenlong LI, Ying LV, Yichao ZHANG, Xiangming QIU, Tingting HUANG. Comparison of Clinical Efficacy of Single-port and Double-port Video-assisted Thoracoscopic Lobectomy in the Treatment of Lung Cancer. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20240419
[5]	Huimin YU, Xin XIN, Zhiwei LIANG. Predictive Value of KIAA1199 and Linc00673 Genes on Chemotherapy Efficacy in Non-small Cell Lung Cancer. Journal of Kunming Medical University,
[6]	Yan LIANG, Lei WANG, Ming LEI, Benchao CHEN, Ping SUN, Shuai LI, Li LIU, Qianrong WANG, Manlin LIAO, Qianli MA. Correlation between KRAS Gene Polymorphism and Non-small Cell Lung Cancer in Yunnan Han Population. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20230210
[7]	Chuntao LI, Xuemei ZHANG, Yandi SU, Jianqing Zhang. Construction of Stable Transfected Cell Line A549 of Non-small Cell Lung Cancer by Overexpressing and Knocking Down LncRNA RP11-521C20.3. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20231016
[8]	Ying-xia WANG, Qin HE, Guo-fang WANG, Xuan ZHANG. Expression and Significance of microRNA-21 and EGFR in Non-small Cell Lung Cancer. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20210818
[9]	Wang Juan , Su Guo Miao , Pan Guo Qing , Bian Li , Yang Zhe , Zeng Ding Tao . . Journal of Kunming Medical University,
[10]	Xiao-biao MA, Feng LUO, Yong-liang GAO, Jing-chao HAO. Clinical Study of Chemotherapy Combined with CIK Cell Immunotherapy for Non-small Cell Lung Cancer. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20201215
[11]	Tang Shi Cong , Pan Hong , Huang Yao Yuan , Zhou Xin , Wang Shou Feng , Zuo Chuan Tian , Mao Nai Quan . . Journal of Kunming Medical University,
[12]	Chen Nan . Observation on the Clinical Efficacy between Pemetrexed Plus Cisplatin and Paclitaxel Plus Cisplatin in the Treatment of Advanced Non-small Eell Lung Cancer. Journal of Kunming Medical University,
[13]	Gu Yong Fang . . Journal of Kunming Medical University,
[14]	Zhou JieYan . . Journal of Kunming Medical University,
[15]	Chen Qiu . . Journal of Kunming Medical University,
[16]	. Clinical Effects of Double-way Chemotherapy on Non-small Cell Lung Cancer with Malignant Pericardial Effusion. Journal of Kunming Medical University,
[17]	. . Journal of Kunming Medical University,
[18]	Jie Yan Hua . Chest X-ray Radiographic and CT Findings in Severe A (H1N1)Virus Infection. Journal of Kunming Medical University,
[19]	Yang Fang . . Journal of Kunming Medical University,
[20]	Zhang Lan Feng . . Journal of Kunming Medical University,